Celltrion

068270.KO

124.52 USD

-1.41

-1.12%

Overview

Last close

124.52 usd

Market cap

26.80B usd

52 week high

167.56 usd

52 week low

92.59 usd

Target price

165.07 usd

Valuation

P/E

N/A

Forward P/E

30.581

Price/Sales

14.4693

Price/Book Value

2.2997

Enterprise Value

27.71B usd

EV/Revenue

13.8578

EV/EBITDA

52.2129

Key financials

Revenue TTM

1.85B usd

Gross Profit TTM

824.60M usd

EBITDA TTM

536.26M usd

Earnings per Share

N/A usd

Dividend

0.35 usd

Total assets

14.57B usd

Net debt

N/A usd

About

Celltrion, Inc., together with its subsidiaries, develops and produces drugs based on proteins for the treatment of oncology in South Korea. The company markets bio pharmaceuticals; generic pharmaceuticals; and covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 that is in phase 3 clinical trial for the treatment of asthma and urticaria; CT-P41, which is in phase 3 clinical trial for the treatment of osteoporosis and bone loss; CT-P42, which is in phase 3 clinical trial for the treatment of diabetic macular edema; and CT-P43 that is in phase 3 clinical trial for the treatment of psoriasis, crohn's disease, and ulcerative colitis. The company also offers CT-P47, which is in phase 3 clinical trial for the treatment of rheumatoid arthritis; and CT-P53 that is is in phase 3 clinical trial for the treatment of multiple sclerosis. Celltrion, Inc. was founded in 2002 and is headquartered in Incheon, South Korea.